Key Stats
- Current price: ~$573
- Q4 2025 total revenue: $790M, +7% YoY
- FY2025 total revenue: surpassed $3B for the first time, +11% YoY
- Tyvaso Q4 revenue: $464M, +12% YoY; Tyvaso DPI +24% YoY
- FY2026 guidance: double-digit revenue growth; $4B annualized run rate by end of 2027
- TIKR model price target: ~$953
- Implied upside: ~66% over ~5 years
Earnings Breakdown: United Therapeutics Crosses $3B in Revenue as Pipeline Transforms the Investment Case
United Therapeutics stock (UTHR) crossed $3 billion in annual revenue for the first time in its history in FY2025, delivering 11% total revenue growth over FY2024, according to President and COO Michael Benkowitz on the Q4 earnings call.
Q4 2025 total revenue came in at $790 million, up 7% year-over-year, with management noting that Q4 and Q1 are historically lighter ordering quarters driven by seasonality in specialty pharmaceutical distribution.
Tyvaso was the primary revenue driver, generating $464 million in Q4 alone, up 12% year-over-year, led by Tyvaso DPI, which grew 24% year-over-year in the quarter.
According to Benkowitz on the Q4 earnings call, referral rates for total Tyvaso through mid-February were at their highest level in two years, with 3 of the last 4 months at or above pre-Liquidia launch levels, suggesting the competitive disruption from Yutrepia has materially faded.
Benkowitz confirmed on the Q4 call that while patient starts lagged referral trends in Q4 due to seasonality and severe weather, the backlog had broken by February, with starts expected to return to sequential revenue growth no later than Q2 2026.
Management also completed a $1 billion share repurchase program, as confirmed by CFO James Edgemond at the TD Cowen Healthcare Conference on March 2, 2026.
The headline financial figures were overshadowed by two pipeline events that arrived within days of the Q4 call: the unblinding of the ADVANCE OUTCOMES trial for ralinepag on March 2, and the disclosure of TreSMI, a new soft mist inhaler formulation, on the Q4 call itself.
Ralinepag, presented at a special call on March 2, 2026, met its primary endpoint with a hazard ratio of 0.45 and p-value below 0.0001, representing a 55% reduction in risk of clinical worsening versus placebo in PAH patients, the majority of whom were on dual background therapy.
United Therapeutics stock is being priced today not primarily on Q4 results, but on the pipeline implications: three projected 2027 commercial launches across ralinepag, TreSMI, and Tyvaso in IPF.
According to Rothblatt at the Leerink Global Healthcare Conference on March 9, 2026, 15,000 ralinepag patients within 24 months of approval would correlate to approximately $3 billion in revenue, against a current annual revenue base of just over $3 billion.
United Therapeutics Stock: What the Financials Show
The quarterly income statement shows a business with stable, high-margin operations beginning to absorb elevated R&D spend, compressing operating margins sequentially even as gross margins hold in the mid-to-high 80s.
Q4 2025 gross margin was 86.9%, modestly below 87.4% in Q3 2025 and 89.7% in Q4 2024, reflecting a gradual downward drift as product mix and cost structure have shifted over the past year.
Q4 2025 operating income was $0.36 billion, an operating margin of 45.2%, down from 48.7% in Q3 2025 and 49.9% in Q4 2024, as SG&A and R&D expenses together reached $0.33 billion in the quarter, the highest level in the trailing eight quarters shown.
The operating margin compression reflects deliberate pipeline investment across the ADVANCE OUTCOMES trial, TreSMI development, and TETON confirmatory studies, not deterioration in the core commercial franchise.
Valuation Model Take and Scenario Breakdown
The TIKR model prices United Therapeutics stock at ~$953, implying about 66% upside from the current price of ~$573, over a 4.7-year horizon at roughly 11% annualized.
The mid-case model assumes revenue CAGR of 16.1% and a net income margin of 41.3%, both within reach given the current $3B revenue base, sustained 45%+ operating margins, and three major product launches expected in 2027.
The ADVANCE OUTCOMES data and TreSMI disclosure materially strengthen the investment case: ralinepag’s hazard ratio of 0.45 in a heavily pretreated population is the kind of result that rewrites a treatment paradigm, and Benkowitz told the TD Cowen Healthcare Conference on March 2, 2026, that ralinepag could reach approximately $2 billion by 2030.
United Therapeutics stock is not priced for a company in harvest mode; it is priced for one still proving a multi-product launch thesis, and the Q4 report and subsequent pipeline data together do more to validate that thesis than any single earnings beat could.
The central tension: United Therapeutics stock’s entire upside case hinges on whether three simultaneous 2027 product launches can be executed cleanly and whether ralinepag penetrates the PAH market as rapidly as management’s projections imply.
What Has to Go Right
- Ralinepag receives FDA approval in mid-2027 as guided, with Benkowitz citing a filing target of mid-2026, and early physician adoption tracks toward the 15,000-patient target Rothblatt described at Leerink as achievable within 24 months of launch.
- TETON 1 replicates the TETON 2 result, where FVC improvement was 95.6 milliliters according to Dr. Peterson on the Q4 earnings call, enabling a Tyvaso IPF sNDA filing by mid-2026 and a commercial launch not later than June 2027.
- Tyvaso DPI sustains its 24% Q4 growth trajectory and referral rates hold at pre-Liquidia launch levels, as confirmed by Benkowitz on the Q4 call, meaning the base revenue engine does not require repair heading into a launch year.
- TreSMI secures FDA approval on a healthy-volunteer-only bioequivalence pathway, which the FDA has confirmed is sufficient per Benkowitz at TD Cowen, allowing a 2027 commercial launch alongside the other two products.
What Could Still Go Wrong
- Operating margin compressed to 45.2% in Q4 2025 from 49.9% a year earlier, and sustaining the model’s 41.3% net income margin assumption through a year of heavy commercialization spending on three simultaneous launches is a significant execution burden.
- Ralinepag’s commercial uptake faces a market where sotatercept is also layering into the same early-treatment PAH population, and any slowdown in physician adoption below the 15,000-patient 24-month target would delay the $3 billion revenue inflection that underpins the valuation case.
- Q4 revenue grew only 7% year-over-year against a 12% full-year FY2025 growth rate, and if the seasonal start backlog takes longer to clear than management’s Q2 2026 target, it signals softer underlying demand trends heading into the launch period.
- Gross margin has compressed from 89.7% in Q4 2024 to 86.9% in Q4 2025, a 280-basis-point decline over four quarters, and if that trajectory continues through launch-year investment, the operating leverage assumption in the TIKR mid-case may not materialize on schedule.
Should You Invest in United Therapeutics Corporation?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up UTHR stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track United Therapeutics Corporation alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze UTHR stock on TIKR for Free →
